🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,931 results for “The” Clear

  1. ATI-045

    Aclaris Therapeutics

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  2. ATI-045, Placebo to ATI-045

    Aclaris Therapeutics

    Atopic dermatitis

    phase 2 small molecule active

    1 trial

  3. ATI-1777

    Aclaris Therapeutics

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  4. ATI-1777 2.0% w/w

    Aclaris Therapeutics

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  5. ATI-2138

    Aclaris Therapeutics

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  6. ATI-450

    Aclaris Therapeutics

    Hidradenitis Suppurativa

    phase 2 small molecule completed

    1 trial

  7. ATI-450

    Aclaris Therapeutics

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  8. ATI-450

    Aclaris Therapeutics

    Psoriatic Arthritis

    phase 2 small molecule terminated

    1 trial

  9. ATI-450

    Aclaris Therapeutics

    Cryopyrin-Associated Periodic Syndrome

    phase 2 small molecule terminated

    1 trial

  10. ATI-450 50 mg oral tablet BID

    Aclaris Therapeutics

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  11. ATI-50002

    Aclaris Therapeutics

    Androgenetic Alopecia

    phase 2 small molecule completed

    1 trial

  12. ATI-50002

    Aclaris Therapeutics

    Alopecia Areata

    phase 2 small molecule completed

    1 trial

  13. ATI-50002 high dose

    Aclaris Therapeutics

    Alopecia Areata

    phase 2 small molecule terminated

    1 trial

  14. ATI-50002 topical solution

    Aclaris Therapeutics

    Vitiligo

    phase 2 small molecule completed

    1 trial

  15. ATI-501 400mg BID (Low dose)

    Aclaris Therapeutics

    Alopecia

    phase 2 small molecule completed

    1 trial

  16. ATI-502

    Aclaris Therapeutics

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  17. ATRN-119

    Aprea Therapeutics

    HPV Positive Oropharyngeal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  18. ATRN-119

    Aprea Therapeutics

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  19. AUR200, Isotone Natriumchloridlösung 0,9 % Braun Injektionslösung

    Aurinia Pharmaceuticals

    Generalized Myasthenia Gravis

    phase 2 small molecule active

    1 trial

  20. AUTO CAR T cell therapy

    Autolus GmbH

    Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy

    phase 2 mab active

    1 trial

  21. AUTO1, Cyclophosphamide 500 mg Powder for Solution for Injection or Infusion, Fludara 50 mg powder for solution for injection or infusion

    Autolus GmbH

    Systemic Lupus Erythematosus with Active Lupus Nephritis

    phase 2 small molecule active

    1 trial

  22. AUTO1, MabThera 500 mg concentrate for solution for infusion, AUTO4, MabThera 100 mg concentrate for solution for infusion

    Autolus GmbH

    Potential malignancy in patients who received treatment with Autolus CAR T cell therapy.

    phase 2 small molecule active

    1 trial

  23. AUTOLOGOUS DENDRITIC CELLS LOADED WITH AUTOLOGOUS TUMOR LYSATE, Tecentriq 1 200 mg concentrate for solution for infusion

    The George Institute

    Lung Cancer

    phase 2 small molecule active

    1 trial

  24. AV-101

    Vistagen Therapeutics

    Parkinson Disease

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources